PR Newswire/Les Echos/
Composition of the Board of Directors of Sanofi
Paris, France - March 5, 2013 - At its meeting held on March 5, 2013, the Board
of Directors of Sanofi decided to propose the appointment of a new independent
Director, Mrs. Fabienne Lecorvaisier, during the General Shareholders' meeting
of May 3, 2013.
As a result of this appointment, the new Board of Directors would be composed
of 16 members, of whom four are women and ten are independent Directors.
The new Board of Directors would consist of the following members: Serge
Weinberg - Chairman, Christopher A. Viehbacher - Chief Executive Officer,
Laurent Attal, Uwe Bicker, Robert Castaigne, Thierry Desmarest, Lord Douro,
Jean-René Fourtou, Claudie Haigneré, Igor Landau, Fabienne Lecorvaisier,
Suet-Fern Lee, Christian Mulliez, Carole Piwnica, Klaus Pohle, Gérard Van
Biography of Mrs. Lecorvaisier
Fabienne Lecorvaisier is a graduate of Ecole Nationale des Ponts & Chaussées
and started her career at Société Générale. She then held various positions
at Barclays Bank and the Banque du Louvre. In 1993, she joined the Essilor
Group as Development Director before being appointed Director Finance and
Information Systems of Essilor America in 1996, then Chief Financial Officer of
the Group in 2001 and Senior Vice-President Strategy and Acquisitions in 2007.
In 2008, Fabienne Lecorvaisier has been appointed Vice-President, Finance and
Administration of the Air Liquide Group, and member of the Group Executive
Committee. She is a board member of Air Liquide USA, Air Liquide Japan and Air
Liquide France Industries.
Mrs. Lecorvaisier received the Legion of Honor medal from the French National
Order in 2010. She is a French citizen.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Media Relations Investor Relations
Jean-Marc Podvin Sébastien Martel
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.
-0- Mar/05/2013 17:31 GMT
Press spacebar to pause and continue. Press esc to stop.